Introduction
============

Cervical cancer (CXCA) is the fourth leading cause of cancer-associated mortality among females worldwide ([@b1-ol-0-0-9549]). The majority of CXCA cases are associated with high risk human papillomavirus (HR-HPV) infection. Among HR-HPV, HPV16 and HPV18 account for 70% of all CXCA cases worldwide ([@b1-ol-0-0-9549]), including in Asian populations ([@b2-ol-0-0-9549]). Epidemiological data revealed an increase in multiple HPV infection from 10% of CXCA cases in 2005 ([@b3-ol-0-0-9549]) to 65% in 2016 ([@b3-ol-0-0-9549]--[@b5-ol-0-0-9549]). However, these figures may reflect a higher sensitivity of detection, resulting in the co-infection of HPV16 and HPV18 being reported as the most common HR-HPV in Africa ([@b6-ol-0-0-9549]) and Asia ([@b7-ol-0-0-9549]), and specifically in Thailand ([@b8-ol-0-0-9549]), as 31.9, 20.8 and 27.8%, respectively. An increased odds ratio of HPV16 and 18 co-infection compared with single infection was demonstrated by Chaturvedi *et al* ([@b9-ol-0-0-9549]) and Trottier *et al* ([@b10-ol-0-0-9549]), but the opposite results were reported by Salazar *et al* ([@b11-ol-0-0-9549]). These controversial findings implied that other viral parameters, not only HPV genotype, may serve important roles in disease progression.

The physical state of HPV infection occurs as one of two forms: An episomal or an integrated form. The episomal state involves the complete life cycle of viral replication in the infected host cells, whereas the integrated form involves integration of HPV DNA into the host DNA, a major genetic event leading to cervical carcinogenesis ([@b12-ol-0-0-9549]). Viral integration and viral load have previously been reported to be biomarkers for cancer with high-grade cervical lesions ([@b13-ol-0-0-9549]). Several methods have been used for the detection of integrated HPV, including polymerase chain reaction (PCR) ([@b14-ol-0-0-9549]), *in situ* hybridization ([@b15-ol-0-0-9549],[@b16-ol-0-0-9549]) and amplification of papillomavirus oncogene transcripts (APOT) ([@b17-ol-0-0-9549]). These are all qualitative measurements. Recently, we established a quantitative PCR of E2 and E6 genes to measure the viral load and physical status of HPV16 DNA in one tube ([@b18-ol-0-0-9549]). A ratio of E2/E6 gene of 1.0 is used to define the episomal form, while a decreased ratio (less than 1.0) indicates the integrated form, due to deletion of the E2 gene during viral integration. The present study demonstrated the benefit of using viral numbers and physical status as surrogate markers of cancer progression.

To the best of our knowledge, the present study was the first to report the simultaneous measurement of 4 genes, E2 and E6 genes of HPV16 and HPV18, in a single tube. The development of multiplex qPCR in the present study provides a total coverage of 70% of HR-HPV-associated CXCA, including single and co-infection of HPV16 and HPV18. The analytical performance of the multiplex qPCR was evaluated in clinical samples, compared with simplex qPCR.

Materials and methods
=====================

### Samples

A total of 20 cervical tissues harboring single or co-infection of HPV16 and HPV18 were collected from 5 pre-cancerous lesions (mean, 42.2±6.6 years) and 15 cancerous lesions (mean, 49.5±13.7 years). Samples were collected between 2002 and 2004 under written informed consents approved by the Ethical Committee of Khon Kaen University, Khon Kaen, Thailand (approval no. HE562296) and between 2013 and 2014 approved by the the Ubonratchathani Cancer Hospital, Ubon Ratchathani, Thailand (approval no. CE012/2013). DNA samples were extracted using a QIAamp Viral DNA kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s protocol. Extracted DNA was used for HPV16 and HPV18 screening by Nested Multiplex PCR, as previously described ([@b19-ol-0-0-9549]).

### Cell culture

The human papillomavirus Caski and HeLa cell lines containing the integrated form of HPV16 (600 DNA copies per cell) and HPV18 (20--50 DNA copies per cell) were used as internal standard for determination of physical status of HPV16 and 18, respectively. HeLa cell line containing HPV18 and CaSki cell line containing HPV16 were used as HPV positive controls. Cells were cultured in 25 cm^2^ flasks at 37°C with 5% CO~2~ in Dulbecco\'s Modified Eagle Medium high glucose (DMEM-HG) media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (10,000 U/ml penicillin and 10 mg/ml streptomycin; all Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). At 70% confluency, cells were trypsinized with 1 ml of 1X trypsin-EDTA at 37°C for 5 min. The cell pellets were collected and centrifuged at 2,000 rpm for 3 min and subsequently used for DNA extraction.

### HPV16 and HPV18 integration status assay

Plasmids containing the whole genomes of HPV16, HPV18, HPV45 and HPV58 (PBR322 for HPV16 and HPV58, PGM4 for HPV18 and HPV45) were provided by Professor Pientong from the Department of Microbiology, Faculty of Medicine, Khon Kaen University. Purified recombinant plasmid copy numbers were estimated by a spectrophotometer concentration measurement (NanoDrop 2000; Thermo Fisher Scientific, Inc.). The DNA calculation formula was 6.02×10^23^ (copies/mol) xA~260~ (ng/ml)/(DNA length ×660)=copies/ml. Plasmid DNA was then diluted with sterile water to obtain between 10^6^ and 10^2^ copies, and was used to establish calibration curves for measuring E2 and E6 by multiplex qPCR using a TaqMan^®^ probe assay (Bioneer Corporation, Daejeon, Korea). The oligonucleotide sequences of primers and probes were followed as previously described ([@b20-ol-0-0-9549],[@b21-ol-0-0-9549]), with modifications to the quencher and reporter fluorescent dyes ([Table I](#tI-ol-0-0-9549){ref-type="table"}). E2 and E6 DNA were amplified using a qPCR thermocycler (Exicycler™; Bioneer Corporation). Each 50 µl reaction mixture contained a premix (AccuPower^®^ DualStar™; Bioneer Corporation) with 0.4 µM probes and primers. The PCR reaction was initiated at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 63°C for 60 sec. Reactions lacking DNA template were used as negative controls as previously described. Quantification of E2 and E6 genes were analyzed using the calibration curve plotted between the quantification cycle (Cq) on the x-axis and the logarithm of the standard copy number on the y-axis (10^2^−10^6^ copies). Linear regression equations were estimated as indicated in [Fig. 1](#f1-ol-0-0-9549){ref-type="fig"}. The obtained Cq from samples were used to calculate E2 and E6 copies from these equations. Amplification efficiency was determined from the slope of log-linear calibration curve (10^−1/slope^−1) ([@b22-ol-0-0-9549]).

### Optimization of temperature for multiplex qPCR

Multiplex qPCR temperature for HPV16 (E2 and E6 genes) and HPV18 (E2 and E6 genes) was optimized. A mixture of 10^5^ copies of plasmids containing the whole genomes of HPV16 and HPV18 was used to optimize the annealing temperature from 55 to 64°C. The temperature that produced the lowest Cq was selected as the optimal annealing temperature.

Evaluation of multiplex qPCR performances
-----------------------------------------

### Multiplex qPCR analytical range

Ten-fold dilutions of mixed HPV16 and HPV18 whole genomic DNA (from 10^2^ to 10^6^ copies) were used as templates for determining the analytical range.

### Multiplex qPCR analytical imprecision

Within-run and between-run precision were each determined using low (10^3^ copies) and high (10^6^ copies) concentrations of whole genome HPV16 and HPV18 DNA mixtures.

### Multiplex qPCR analytical specificity

Cross-reactivity with two other HPV genotypes, HPV45 and HPV58, was tested. No fluorescent signal indicated a lack of cross-reaction, and uninfected HPV DNA was used as a negative control.

### Competitive effect of HPV16 and HPV18 in multiplex qPCR

A mixture of unequal concentrations of HPV16 and HPV18 DNA (from 10^3^ to 10^6^ copies) was used to evaluate competitive effects in multiplex qPCR. E2 and E6 copies obtained from unequal HPV16 and HPV18 templates (test) were compared to those determined using a single template of HPV16 or HPV18 (control) by a paired t-test. No significant difference (P\>0.05) indicated no competitive effect.

### Evaluation of physical status using multiplex qPCR in clinical samples

The cut-off value for an episomal form (complete E2 and E6 sequence) was first determined using plasmid DNA containing whole HPV16 and HPV18 genomes. The E2/E6 ratio was calculated by the 95% confidence interval (CI) and used to interpret physical status in clinical samples as previously described ([@b18-ol-0-0-9549]). To verify the accuracy of the multiplex qPCR of HPV16 and HPV18, 10^5^ copies of Caski and HeLa cells containing pure integrated HPV16 and HPV18, respectively, were prepared according to the DNA calculation formula and used as internal standards for the integrated form. A total of 10^5^ copies of whole plasmid genome HPV16 and HPV18 were used as internal standards for the episomal form. The two cell lines were provided by Professor Pientong. A total of 20 cervical samples with single and mixed infection were used to compare the copy number and physical status between the simplex and multiplex qPCR using paired t-tests and χ^2^ tests.

### Statistical analysis

The linear regression equation was estimated from standard curves between viral copy number (y-axis) and cycle time (x-axis). The percentage of efficiency between 80--120% and correlation (R^2^) \>0.98 were used to determine the standard curve. The comparison of viral copy number between multiplex and simplex was performed using paired t-tests, while physical status was compared by χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS 19 software (IBM Corp., Armonk, NY, USA) under a Khon Kaen University license.

Results
=======

### Multiplex qPCR performance for the detection of HPV16 and HPV18 (E2 and E6 genes)

The optimization of Cq was performed under annealing temperatures from 55 to 64°C, as demonstrated in [Fig. 2](#f2-ol-0-0-9549){ref-type="fig"}. The optimal Cq for the E2 and E6 genes of HPV16 was 63°C, whereas the optimal Cq for HPV18 was between 55 and 64°C. Therefore, 63°C was used to construct a standard curve for HPV16 and HPV18 multiplex qPCR, as demonstrated in [Fig. 1](#f1-ol-0-0-9549){ref-type="fig"}. According to the guidelines for validation of quantitative PCR methods, linear regression and correlation (R^2^) analyses for each gene revealed an acceptable efficiency of 109--115% ([@b23-ol-0-0-9549]). The analytical range was verified at 1,000-1,000,000 copies for HPV16 and HPV18, with average imprecision from 0.42 to 0.50% CV as demonstrated in [Fig. 1](#f1-ol-0-0-9549){ref-type="fig"}. The imprecision of measured HPV copies is presented in [Table II](#tII-ol-0-0-9549){ref-type="table"}. The average CV of within-run and between-run was 10.2 and 12.1, respectively. No cross reactivity was observed with HPV58 and HPV45 ([Fig. 3](#f3-ol-0-0-9549){ref-type="fig"}).

### Evaluation of competitive effect of unequal HPV16 and HPV18 template concentrations in multiplex qPCR

To mimic the presence of HPV16 and HPV18 co-infection up to 1,000-fold difference in the same sample, measurement of mixed HPV16 and HPV18 DNA was compared in parallel with that of single HPV16 and HPV18. Different concentrations of HPV16 and HPV18 exhibited no effect on the quantification of E2 (P=0.319 and P=0.526, respectively) and E6 genes (P=0.347 and P=0.146, respectively), as demonstrated in [Tables III](#tIII-ol-0-0-9549){ref-type="table"} and [IV](#tIV-ol-0-0-9549){ref-type="table"}. Therefore, our established multiplex qPCR platform provided an accurate measurement for the presence of HPV16 and HPV18 co-infection.

### Evaluation of physical status in clinical samples

Cut-off values for viral status were calculated as previously described by Wanram *et al* ([@b18-ol-0-0-9549]) and are shown in [Table V](#tV-ol-0-0-9549){ref-type="table"}. The E2/E6 ratio was identified as 0.78--1.10 and 0.85--1.18 for HPV16 and HPV18, respectively. An E2/E6 ratio of 0 was defined as the absolute integrated form, whereas E2/E6 \>0 and less than the cut-off value was interpreted as the mixed form of episomal and integrated HPV ([@b18-ol-0-0-9549]). Comparisons of HPV16 and HPV18 copy numbers between the simplex and multiplex qPCR in CXCA samples are summarized in [Table VI](#tVI-ol-0-0-9549){ref-type="table"}. No significant difference between simplex and multiplex qPCR was observed for HPV16 E2 and E6 (P=0.307 and P=0.288; paired t-test) and HPV18 E2 and E6 genes (P=0.396 and P=0252; paired t-test). The physical status obtained from multiplex qPCR was also compared with that from the simplex qPCR. The cut-off value for the episomal form of HPV16 (0.79--1.10) and HPV18 (0.85--1.18) was calculated as previously described for multiplex qPCR. Interpretation of physical status was similar in 95% (19/20) of cases between multiplex and simplex qPCR assays, and differed in one case, CX-1 (P=0.372; χ^2^ test; [Table VI](#tVI-ol-0-0-9549){ref-type="table"}).

Discussion
==========

Multiple HR-HPV infection, particularly HPV16 and HPV18 co-infection, is now a concern due to its effects on cervical neoplasia development. The failure rate of treatment was previously reported to be increased by 5-fold in multiple infection (57%), compared with single infection (12%) ([@b24-ol-0-0-9549]). Therefore, a suitable risk assessment among patients with persistent multiple HR-HPV infection is required. To assess the risk, viral load and viral physical status may be used for cancer prognosis. In the present study, a one tube qPCR assay for HPV16 and HPV18 co-infection was successfully established with acceptable performance in terms of specificity, accuracy and precision.

Upon performing a literature search for multiplex qPCR of 4 genes in one tube, one study by Zhao *et al* ([@b25-ol-0-0-9549]) was identified. The authors reported detection of 4 viral DNAs: HPV16 (E6 gene), HPV18 (E6 gene), HSV1 and HSV2, with an improved detection limit at 10 copies compared with the present study. The difference in the detection limit may result from the different size of viral DNA standard. Small fragments of viral DNA (66--139 bp) were used as standard in the study undertaken by Zhao *et al*, whereas the whole HPV genome (10728--12267 bp) was used in the present study. Accordingly, the small size template has an advantage for amplification when compared with the whole genome. Therefore, our established technique better represents the real viral infection in a clinical setting. To resolve this limitation, more DNA template may be adjusted. The accuracy of interpretation, including possible cross reactivity, was verified using DNA of known viral status from cervical Caski and HeLa cell lines. HPV58 and HPV45 were selected for cross reactivity according to the top 4 common HR-HPV types (HPV 16, 18, 45 and 58), covering 90% of cases among Thai women ([@b26-ol-0-0-9549]). Accurate quantification was not only demonstrated via comparison with simplex qPCR, but it was also revealed that there was no competitive effect of an unequal mixed HPV DNA template from 10- to 1,000-fold ([Tables III](#tIII-ol-0-0-9549){ref-type="table"} and [IV](#tIV-ol-0-0-9549){ref-type="table"}).

Furthermore, the comparison of viral physical status between simplex and multiplex qPCR in clinical samples achieved 95% (19/20 samples) agreement in the results of viral physical status. The different physical status of CX1 was caused by the variation of E2/E6 ratio between simplex (0.75) and multiplex (0.81) which closed to the cut-off value for episomal form (0.79 and 0.78) resulting in discrepancy results as mixed form and episomal form, respectively. This limitation of accuracy occurred at values close to the cut-off values.

In conclusion, the increased incidence of HPV16 and HPV18 co-infection is a high-risk factor for CXCA progression in patients with persistent HR-HPV infection. Therefore, the successful development of multiplex qPCR for detecting HPV16 and HPV18 viral load and physical status in a single tube would provide a significant benefit in terms of cost effectiveness and shorter assay time in the clinic. To assess the potential of using this assay as a risk assessment for cancer progression in patients with single and co-infection with HPV16 and HPV18, a larger sample size with clinical outcome data should be included in future studies. In particular, pre-cancerous and early cancerous cases harboring high risk factors should be followed up frequently with monitoring of risk factors.

Clinical stage of samples were provided by Dr Metee Wongsena (Chief of Gynecologic Cancer Department, Ubonratchathani Cancer Center, Ubonratchathani, Thailand) and Dr Pissamai Yuenyao (Srinagarind Hospital, Khon Kaen, Thailand).
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![Standard curves of multiplex quantitative polymerase chain reaction for E2 and E6 genes of HPV16 and HPV18. The analytical range was revealed to be 10^3^ to 10^6^ copies. HPV, human papillomavirus; SD, standard deviation.](ol-16-06-6977-g00){#f1-ol-0-0-9549}

![Optimization for (A) E2 and (B) E6 genes of HPV16, and (C) E2 and (D) E6 genes of HPV18. The optimal Cq for HPV16 and HPV18 was selected at 63°C. HPV, human papillomavirus; Cq, quantification cycle.](ol-16-06-6977-g01){#f2-ol-0-0-9549}

![Analytical specificity of multiplex quantitative polymerase chain reaction. No cross reactivity was observed with 10^4^ copies of HPV45 and HPV58. Uninfected HPV DNA was used as a negative control. HPV, human papillomavirus.](ol-16-06-6977-g02){#f3-ol-0-0-9549}

###### 

Oligonucleotide sequences and TaqMan^®^ probes used for amplification of E2 and E6 genes of HPV16 and HPV18.

  HPV type   Name                      Sequence (5′-3′)                                  Amplified product length (bp)   (Refs.)
  ---------- ------------------------- ------------------------------------------------- ------------------------------- -----------------------------
  HPV16      HPV16 E2 Forward primer   AACGAAGTATCCTCTCCTGAAATTATTAG                     82                              Peitsaro *et al*, 2002 (20)
             HPV16 E2 Reverse primer   CCAAGGCGACGGCTTTG                                                                 
             HPV16 E2 Probe            (TAMRA)-CACCCCGCCGCGACCCATA-(BHQ)                                                 
             HPV16 E6 Forward primer   GAGAACTGCAATGTTTCAGGACG                           81                              
             HPV16 E6 Reverse primer   TGTATAGTTGTTTGCAGCTCTGTGC                                                         
             HPV16 E6 gene Probe       (Texus red)-CAGGAGCGACCCAGAAAGTTACCACAGTT-(BHQ)                                   
  HPV18      HPV18 E2 Forward primer   AGAAGCAGCATTGTGGACCT                              167                             Damay *et al*, 2009 (21)
             HPV18 E2 Reverse primer   GGTCGCTATGTTTTCGCAAT                                                              
             HPV18 E2 Probe            (TeT)-TCAACC-CACTTCTCGGTGCAGC-(BHQ)                                               
             HPV18 E6 Forward primer   TCACAACATAGCTGGGCACT                              91                              
             HPV18 E6 Reverse primer   CTTGTGTTTCTCTGCGTCGT                                                              
             HPV18 E6 Probe            (FAM)-GCCATTCGTGCTGCAACCGA-(BHQ)                                                  

HPV, human papillomavirus; bp, base pairs.

###### 

Analytical imprecision of the HPV16 (E2 and E6 genes) and HPV18 (E2 and E6 genes) measurement using multiplex quantitative polymerase chain reaction.

                                                                    HPV16 E2 gene           HPV16 E6 gene                                            
  ----------------------------------------------------------------- ----------------------- -------------------------------- ----------------------- --------------------------------
  Within-run (n=12)^[a](#tfn2-ol-0-0-9549){ref-type="table-fn"}^                                                                                     
  Low level^[c](#tfn4-ol-0-0-9549){ref-type="table-fn"}^            32.41±0.18 (0.54)       961±127.1 (13.23)                33.67±0.17 (0.52)       1,084±149.1 (13.74)
  High level^[d](#tfn5-ol-0-0-9549){ref-type="table-fn"}^           23.11±0.08 (0.35)       952,490±59,040.35 (6.19)         24.59±0.10 (0.39)       1,097,119±81,784.1 (7.45)
  Between-run (n=15)^[b](#tfn3-ol-0-0-9549){ref-type="table-fn"}^                                                                                    
  Low level^[c](#tfn4-ol-0-0-9549){ref-type="table-fn"}^            32.61±0.20 (0.60)       973±141.36 (14.53)               34.26±0.19 (0.54)       929±137.45 (14.79)
  High level^[d](#tfn5-ol-0-0-9549){ref-type="table-fn"}^           23.37±0.14 (0.59)       911,140±91,626.87 (10.06)        25.04±0.14 (0.55)       1,040,597±112,028.74 (10.77)
                                                                                                                                                     
                                                                    **HPV18 E2 gene**       **HPV18 E6 gene**                                        
                                                                                                                                                     
  **Precision**                                                     **Mean ± SD (CV) Cq**   **Mean ± SD (CV) Copy number**   **Mean ± SD (CV) Cq**   **Mean ± SD (CV) Copy number**
                                                                                                                                                     
  Within-run (n=12)^[a](#tfn2-ol-0-0-9549){ref-type="table-fn"}^                                                                                     
    Low level^[c](#tfn4-ol-0-0-9549){ref-type="table-fn"}^          33.47±0.17 (0.52)       1,159±160.1 (13.81)              34.83±0.18 (0.52)       1,067±144.35 (13.52)
    High level^[d](#tfn5-ol-0-0-9549){ref-type="table-fn"}^         24.61±0.07 (0.29)       1,123,790±60,126.32 (5.4)        25.73±0.11 (0.44)       1,023,242±86,472.54 (8.45)
  Between-run (n=15)^[b](#tfn3-ol-0-0-9549){ref-type="table-fn"}^                                                                                    
    Low level^[c](#tfn4-ol-0-0-9549){ref-type="table-fn"}^          34.03±0.19 (0.57)       996±147.1 (14.76)                34.77±0.19 (0.53)       958±134.18 (14.00)
    High level^[d](#tfn5-ol-0-0-9549){ref-type="table-fn"}^         25.00±0.11 (0.43)       992,011±81,890.14 (8.25)         25.42±0.13 (0.51)       1,054,498±101,053.01 (9.58)

12 replicates per experiment

Triplicate in 5 independent experiments

10^3^ copies of HPV16 and HPV18 DNA

10^6^ copies of HPV16 and HPV18 DNA. HPV, human papillomavirus; Cq, quantification cycle.

###### 

Competitive effect of unequal DNA copies between HPV16 and HPV18 on the measurement of HPV16 E2 and E6 genes using multiplex quantitative polymerase chain reaction.

  HPVE2 gene      HPVE6 gene                                                                                                                                                                                                              
  --------------- ------------------------------------------------------------ --------- -------------------------------------------------------- --------------- ------------------------------------------------------------ ---------- --------------------------------------------------------
  Copy Ratio      Measured                                                     Copy of   Measured copies                                          Copy Ratio      Measured                                                     Copy       Measured copies
  (HPV16:HPV18)   copies (Test)^[a](#tfn6-ol-0-0-9549){ref-type="table-fn"}^   HPV16     (Control)^[a](#tfn6-ol-0-0-9549){ref-type="table-fn"}^   (HPV16:HPV18)   copies (Test)^[a](#tfn6-ol-0-0-9549){ref-type="table-fn"}^   of HPV16   (Control)^[a](#tfn6-ol-0-0-9549){ref-type="table-fn"}^
  10^6^:10^3^     945,367                                                      10^6^     1,026,287                                                10^6^:10^3^     979,497                                                      10^6^      1,039,326
  10^6^:10^4^     901,450                                                      10^6^     915,772                                                  10^6^:10^4^     900,328                                                      10^6^      913,776
  10^6^:10^5^     921,335                                                      10^6^     897,221                                                  10^6^:10^5^     914,673                                                      10^6^      911,439
  10^6^:10^6^     979,241                                                      10^6^     980,160                                                  10^6^:10^6^     1,039,326                                                    10^6^      964,189
  10^5^:10^3^     89,554                                                       10^5^     90,112                                                   10^5^:10^3^     87,556                                                       10^5^      89,341
  10^5^:10^4^     95,749                                                       10^5^     103,356                                                  10^5^:10^4^     91,586                                                       10^5^      98,371
  10^5^:10^5^     96,968                                                       10^5^     105,065                                                  10^5^:10^5^     97,092                                                       10^5^      103,174
  10^5^:10^6^     94,159                                                       10^5^     92,332                                                   10^5^:10^6^     112,708                                                      10^5^      100,329
  10^4^:10^3^     8,832                                                        10^4^     9,149                                                    10^4^:10^3^     11,219                                                       10^4^      10,439
  10^4^:10^4^     8,836                                                        10^4^     10,626                                                   10^4^:10^4^     9,175                                                        10^4^      9,303
  10^4^:10^5^     8,913                                                        10^4^     9,319                                                    10^4^:10^5^     8,641                                                        10^4^      10,322
  10^4^:10^6^     11,347                                                       10^4^     10,861                                                   10^4^:10^6^     10,989                                                       10^4^      9,018
  10^3^:10^3^     1,143                                                        10^3^     1,200                                                    10^3^:10^3^     1,039                                                        10^3^      1,153
  10^3^:10^4^     867                                                          10^3^     912                                                      10^3^:10^4^     907                                                          10^3^      865
  10^3^:10^5^     881                                                          10^3^     1,122                                                    10^3^:10^5^     848                                                          10^3^      973
  10^3^:10^6^     848                                                          10^3^     901                                                      10^3^:10^6^     846                                                          10^3^      908

Non-significant differences between test and control for HPV16 E2 (P=0.319; paired Student\'s t-test) and HPV16 E6 (P=0.347; paired Student\'s t-test). HPV, human papillomavirus.

###### 

Competitive effect of unequal copies between HPV16 and HPV18 on the measurement of HPV18 E2 and E6 genes using multiplex quantitative polymerase chain reaction.

  HPVE2 gene      HPVE6 gene                                                                                                                                                                                                                             
  --------------- ---------------------------------------------------------------- --------- ---------------------------------------------------------------- --------------- ---------------------------------------------------------------- --------- ----------------------------------------------------------------
  Copy ratio      Measured copies                                                  Copy of   Measured copies of                                               Copy ratio      Measured copies                                                  Copy of   Measured copies of
  (HPV18:HPV16)   of HPV18E2 (Test)^[a](#tfn7-ol-0-0-9549){ref-type="table-fn"}^   HPV18     HPV18E2 (Control)^[a](#tfn7-ol-0-0-9549){ref-type="table-fn"}^   (HPV18:HPV16)   of HPV18E6 (Test)^[a](#tfn7-ol-0-0-9549){ref-type="table-fn"}^   HPV18     HPV18E6 (Control)^[a](#tfn7-ol-0-0-9549){ref-type="table-fn"}^
  10^6^:10^3^     1,135,661                                                        10^6^     1,075,620                                                        10^6^:10^3^     1,015,464                                                        10^6^     1,107,241
  10^6^:10^4^     1,097,976                                                        10^6^     1,181,450                                                        10^6^:10^4^     1,107,170                                                        10^6^     1,125,579
  10^6^:10^5^     877,385                                                          10^6^     1,135,265                                                        10^6^:10^5^     911,742                                                          10^6^     893,768
  10^6^:10^6^     1,092,086                                                        10^6^     993,922                                                          10^6^:10^6^     965,678                                                          10^6^     1,040,114
  10^5^:10^3^     104,611                                                          10^5^     96,998                                                           10^5^:10^3^     90,546                                                           10^5^     94,778
  10^5^:10^4^     101,164                                                          10^5^     113,785                                                          10^5^:10^4^     97,952                                                           10^5^     113,933
  10^5^:10^5^     105,464                                                          10^5^     101,469                                                          10^5^:10^5^     110,175                                                          10^5^     87,996
  10^5^:10^6^     102,760                                                          10^5^     113,715                                                          10^5^:10^6^     87,492                                                           10^5^     107,587
  10^4^:10^3^     9,129                                                            10^4^     8,789                                                            10^4^:10^3^     10,201                                                           10^4^     9,746
  10^4^:10^4^     9,550                                                            10^4^     9,443                                                            10^4^:10^4^     9,732                                                            10^4^     10,395
  10^4^:10^5^     8,639                                                            10^4^     9,988                                                            10^4^:10^5^     10,403                                                           10^4^     8,665
  10^4^:10^6^     10,700                                                           10^4^     9,812                                                            10^4^:10^6^     8,910                                                            10^4^     10,550
  10^3^:10^3^     912                                                              10^3^     1,120                                                            10^3^:10^3^     937                                                              10^3^     1,056
  10^3^:10^4^     936                                                              10^3^     1,078                                                            10^3^:10^4^     910                                                              10^3^     938
  10^3^:10^5^     849                                                              10^3^     831                                                              10^3^:10^5^     901                                                              10^3^     833
  10^3^:10^6^     896                                                              10^3^     1,168                                                            10^3^:10^6^     869                                                              10^3^     1,063

Non-significant difference between test and control for HPV18E2 (P=0.526; paired t-test) and HPV18E6 (P=0.146; paired t-test). HPV, human papillomavirus.

###### 

Estimation of cut-off values (E2 and E6 ratios) for the interpretation of physical status using various concentrations of whole genome plasmid DNA from 10^4^ to 10^6^ copies.

               HPV16       HPV18                                              
  ---- ------- ----------- ------------ ------------ ----------- ------------ ------------
  1    10^3^   1,115       1,103        1.01         1,153       1,233        0.94
  2    10^3^   1,115       1,185        0.94         1,019       1,210        0.84
  3    10^3^   908         1,044        0.87         1,193       1,211        0.99
  4    10^3^   1,168       1,169        1            1,155       1,134        1.02
  5    10^3^   1,038       1,047        0.99         1,146       1,179        0.97
  6    10^4^   8,882       10,814       0.82         10,760      9,858        1.09
  7    10^4^   8,789       10,438       0.84         9,187       9,408        0.98
  8    10^4^   9,019       10,379       0.87         8,703       9,062        0.96
  9    10^4^   9,233       9,268        1            8,513       8,220        1.04
  10   10^4^   9,117       9,337        0.98         9,687       11,622       0.83
  11   10^5^   94,603      105,819      0.89         110,462     107,970      1.02
  12   10^5^   108,055     108,928      0.99         107,699     102,882      1.05
  13   10^5^   88,246      100,449      0.88         106,389     98,269       1.08
  14   10^5^   87,938      105,370      0.83         114,166     112,276      1.02
  15   10^5^   106,246     100,978      1.05         109,971     113,442      0.97
  16   10^6^   1,098,531   1,059,641    1.04         1,086,195   991,320      1.1
  17   10^6^   926,410     982,153      0.94         1,097,976   996,524      1.1
  18   10^6^   912,783     1,076,185    0.85         1,085,161   927,645      1.17
  19   10^6^   1,020,080   931,143      1.1          1,086,195   1,005,826    1.08
  20   10^6^   940,240     997,234      0.94         1,146,435   1,142,588    1
                           Mean         0.94                     Mean         1.01
                           SD           0.08                     SD           0.08
                           Mean ± 2SD   0.78--1.10               Mean ± 2SD   0.85--1.18

HPV, human papillomavirus; SD, standard deviation.

###### 

Comparison of viral copy number and physical status determination between multiplex qPCR (test) and simplex qPCR (control) in 20 cervical tissues samples harboring single and co-infection of HPV16 and HPV18.

                        Simplex qPCR (Control)   Multiplex qPCR (Test)                                                                                                                                     
  --------------------- ------------------------ ----------------------- ------ ------------ -------- --------- ------ ------------ ----------- ----------- ------ ------------ --------- --------- ------ ------------
  PCX 1 (16)            5,139                    498,762                 0.01   Mixed        --       --        --     --           4,196       470,492     0.01   Mixed        --        --        --     --
  PCX 2 (16)            312                      32,190                  0.01   Mixed        --       --        --     --           203         30,613      0.01   Mixed        --        --        --     --
  PCX 3 (16)            5,815                    6,087                   0.96   Episomal     --       --        --     --           5644.39     6196.23     0.91   Episomal     --        --        --     --
  PCX 4 (18)            --                       --                      --     --           --       191,065   0      Integrated   --          --          --     --           --        153,540   0      Integrated
  PCX 5 (18)            --                       --                      --     --           --       9,380     0      Integrated   --          --          --     --           --        11,897    0      Integrated
  CX 1 (16)             118,584                  157,522                 0.75   Mixed        --       --        --     --           108,968     133,776     0.81   Episomal     --        --        --     
  CX2 (16)              30,353                   26,353                  1.15   Episomal     --       --        --     --           32,588      24,118      1.35   Episomal     --        --        --     
  CX 3 (16)             --                       24,237                  0      Integrated   --       --        --     --           --          26,814      0      Integrated   --        --        --     
  CX 4 (16)             38,041                   44,122                  0.86   Episomal     --       --        --     --           38,788      48,108      0.81   Episomal     --        --        --     
  CX 5 (16)             6,209                    6,721                   0.92   Episomal     --       --        --     --           6,879       7,395       0.93   Episomal     --        --        --     
  CX 6 (18)             --                       --                      --     --           15,649   45,455    0.34   Mixed        --          --          --     --           16,857    42,240    0.4    Mixed
  CX 7 (18)             --                       --                      --     --           --       73,929    0      Integrated   --          --          --     --           --        70,912    0      Integrated
  CX 8 (18)             --                       --                      --     --           74,237   56,271    1.32   Episomal     --          --          --     --           71,243    54,039    1.32   Episomal
  CX 9 (16+18)          855                      3,468                   0.25   Mixed        326      521       0.63   Mixed        1,014       3,919       0.26   Mixed        205       420       0.49   Mixed
  CX 10 (16+18)         39,350                   123,420                 0.32   Mixed        266      410       0.65   Mixed        36,000      155,429     0.23   Mixed        113       237       0.48   Mixed
  CX 11 (16+18)         2,834,887                6,008,765               0.47   Mixed        4,090    3,087     1.32   Episomal     2,592,857   5,571,429   0.47   Mixed        3,064     2,414     1.27   Episomal
  CX 12 (16+18)         4,122                    14,979                  0.28   Mixed        403      478       0.84   Episomal     3,305       17,360      0.19   Mixed        371       356       1.04   Episomal
  CX 13 (16+18)         120                      277                     0.43   Mixed        219      415       0.53   Mixed        92          227         0.41   Mixed        197       339       0.58   Mixed
  CX 14 (16+18)         9,124                    24,510                  0.37   Mixed        --       1,034     0      Integrated   8,733       20,600      0.42   Mixed        --        853       0      Integrated
  CX 15 (16+18)         --                       512,980                 0      Integrated   --       981       0      Integrated   --          488,500     0      Integrated   --        741       0      Integrated
  Internal control                                                                                                                                                                                         
  HPV16; Caski          0                        95,859                  0      Integrated   0        0         0      --           0           91,791      0      Integrated   0         0         0      --
  HPV18; HeLa           0                        0                       0      --           0        102,825   0      Integrated   0           0           0      --           0         110,275   0      Integrated
  Whole plasmid HPV16   109,334                  102,675                 1.06   Episomal     --       --        --     --           106,445     105,988     1.00   Episomal     --        --        --     --
  Whole plasmid HPV18   --                       --                      --     --           99,545   98,9655   1.01   Episomal     --          --          --     --           100,599   99,453    1.01   Episomal

The cut-off value of physical status interpretation for

HPV16

HPV18 using simplex qPCR; for

HPV16

HPV18 using multiplex qPCR. There was no significant difference in copy numbers between simplex and multiplex qPCR for HPV16 E2 gene (P=0.307; paired t-test); HPV16 E6 gene (P=0.288; paired t-test). There was no significant difference in copy numbers between simplex and multiplex qPCR for HPV18 E2 gene (P=0.396; paired t-test); HPV18 E6 gene (P=0.252; paired t-test). There was no significant difference in physical status from multiplex qPCR compared with simplex qPCR (P=0.372; χ^2^ test). Caski and HeLa cell lines containing 100,000 copies of E6 gene were used as internal standard for integrated HPV16 and HPV18/Whole plasmid HPV16 and HPV18 100,000 copies of E2 and E6 genes were used as internal standard for episomal HPV16 and HPV18. qPCR, quantitative polymerase chain reaction; HPV, human papillomavirus; PCX, pre-cancerous cervical tissues; CX, cervical cancer tissues.
